Company intelligence / Profile preview

Himuka AM Pharma

Miyazaki, Miyazaki, Japanhimuka-am.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Himuka AM Pharma is a clinical-stage biotech company developing novel therapies based on improved adrenomedullin peptides. Its lead candidate, HM201, targets the adrenomedullin receptor and is in Phase 1 clinical trials for inflammatory bowel diseases such as ulcerative colitis. Preclinical studies have shown efficacy in animal models and potential applications are being explored for other indications including cerebral infarction and severe pneumonia from COVID‑19. The company has raised approximately $11M to date and remains active with ongoing R&D efforts. No published human efficacy results yet.

Therapeutic areas: GastroenterologyNeurologyInfectious Diseases
Modalities: Synthetic peptideSmall molecule drug
Industry: Biotech

Drug pipeline

1 asset

HM201

Partnerships

Syneos Health Inc.

Beyond the preview

Go deeper on Himuka AM Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Himuka AM Pharma.

Explore the full profile